Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613162 | 0.90 | HRH4 (0.37) | CACNA1HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25613150 | 0.85 | ULK1 (0.31) | FEN1 | |
| SCHEMBL25613142 | 0.81 | PIK3CA (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19367958 | 0.78 | FEN1 (0.36) | FEN1 | |
| SCHEMBL25613158 | 0.74 | MAP3K11 (0.36) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25613148 | 0.73 | KDM4E (0.38) | FEN1 | |
| SCHEMBL25613161 | 0.73 | KDM4E (0.40) | CACNA1B | |
| SCHEMBL25613079 | 0.73 | FEN1 (0.34) | SLC6A2SLC6A4SLC6A3FEN1 | |
| SCHEMBL25613412 | 0.72 | FEN1 (0.33) | FEN1 | |
| SCHEMBL25613108 | 0.71 | ULK1 (0.39) | FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | CACNA1G 2874/4885CACNA1H 3705/4885CACNA1C 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.